Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$20.0 million","newsHeadline":"Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Asahi Kasei Finechem","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea\u2019s Partner Asahi Kasei Pharma Completes Patient Enrolment in Phase 3 Study with Antifungal Isavuconazole (Cresemba\u00ae) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea\u2019s Partner Asahi Kasei Pharma Prepares NDA Filing for the Marketing Authorization of Isavuconazole in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$72.3 million","upfrontCash":"$7.5 million","newsHeadline":"Basilea\u2019s Partner Asahi Kasei Pharma Filed New Drug Application For the Marketing Authorization of Isavuconazole in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"VectivBio","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"$30.0 million","newsHeadline":"VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"VectivBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$72.3 million","upfrontCash":"$7.5 million","newsHeadline":"Basilea Announces CHF 5 Million Milestone Payment From Asahi Kasei Pharma For Antifungal Cresemba\u00ae (isavuconazole) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Asahi Kasei Pharma

    Menu

    Asahi Kasei Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Asahi Kasei Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea Announces CHF 5 Million Milestone Payment From Asahi Kasei Pharma For Antifungal Cresemba® (isavuconazole) in Japan

              Details:

              Under the terms of the initial agreement, Asahi Kasei Pharma received exclusive rights to develop and commercialize Basilea’s antifungal Cresemba (isavuconazole), an intravenous and oral azole antifungal, in Japan.

              Lead Product(s): Isavuconazonium Sulfate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Basilea Pharmaceutica

              Deal Size: $72.3 million Upfront Cash: $7.5 million

              Deal Type: Licensing Agreement March 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Asahi Kasei Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan

              Details:

              Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.

              Lead Product(s): Apraglutide

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Peptide

              Recipient: VectivBio

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Asahi Kasei Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression

              Details:

              VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

              Lead Product(s): VEL-101

              Therapeutic Area: Immunology Product Name: FR104

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Veloxis Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Asahi Kasei Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

              Details:

              The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-host disease in Japan.

              Lead Product(s): Apraglutide

              Therapeutic Area: Gastroenterology Product Name: FE203799

              Highest Development Status: Phase III Product Type: Peptide

              Recipient: VectivBio

              Deal Size: $200.0 million Upfront Cash: $30.0 million

              Deal Type: Licensing Agreement March 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Asahi Kasei Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea’s Partner Asahi Kasei Pharma Filed New Drug Application For the Marketing Authorization of Isavuconazole in Japan

              Details:

              Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan.

              Lead Product(s): Isavuconazonium Sulfate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Basilea Pharmaceutica

              Deal Size: $72.3 million Upfront Cash: $7.5 million

              Deal Type: Partnership September 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Asahi Kasei Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea’s Partner Asahi Kasei Pharma Prepares NDA Filing for the Marketing Authorization of Isavuconazole in Japan

              Details:

              The phase 3, multi-center, open-label study enrolled 103 patients and was assessing the safety and efficacy of intravenously or orally administered isavuconazole for the treatment of adult Japanese patients suffering from deep-seated mycoses.

              Lead Product(s): Isavuconazonium Sulfate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Basilea Pharmaceutica

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Asahi Kasei Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

              Details:

              Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.

              Lead Product(s): AK1780

              Therapeutic Area: Neurology Product Name: AK1780

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $410.0 million Upfront Cash: $20.0 million

              Deal Type: Licensing Agreement January 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Asahi Kasei Finechem

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea’s Partner Asahi Kasei Pharma Completes Patient Enrolment in Phase 3 Study with Antifungal Isavuconazole (Cresemba®) in Japan

              Details:

              The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.

              Lead Product(s): Isavuconazonium Sulfate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Basilea Pharmaceutica

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY